Default understanding: TESTS! yes, DNA marker tests
If InoLife captures JUST 5% of the existing market share for TESTING METABOLIC RATE BECAUSE OF THE NEW FDA BLACK BOX WARNING and the 6M new prescriptions in the next 3 months, this is what the stock price would be at $250 cost:
$5.56
That's EBITDA, etc. But also without a multiple.
Lop off 40% for margin of error, and it's $3.34
Imagine if 50% market share, or 80%
legend:
5%Mkt share * 9M new Plavix users 3 months = 450,000
5%Mkt share * 48M Plavix users = 2.4M
128 OS
$250 cost